文献速递肝病

Saroglitazar治疗原发性胆汁性胆管炎的2b/3期试验

A phase 2b/3 trial of saroglitazar in primary biliary cholangitis.
PubMed 文献 · Hepatology · 2026-10-26

EPICS-III为2b/3期适应性双盲随机对照试验,评估Saroglitazar对UDCA应答不佳或不耐受的PBC患者的疗效。3期纳入148例,52周生化应答率56.7% vs 安慰剂9.8%(差48.0%,95%CI 35.3-60.8,p<0.001),ALP正常化8.2% vs 0%(p=0.016),耐受良好。

要点

  • Saroglitazar 0.97mg显著提高52周生化应答率(56.7% vs 9.8%)。
  • ALP正常化率8.2% vs 0%,差异有统计学意义。
  • 基线ALP≤3xULN者应答率更高(79.0% vs 14.3%)。

核心结论

  • Saroglitazar 0.97mg可显著改善UDCA应答不佳或不耐受PBC患者的生化应答和ALP正常化,52周内耐受良好。

研究设计与样本

  • EPICS-III为2b/3期适应性双盲随机对照试验,纳入对UDCA应答不佳或不耐受的PBC患者。
  • 2b期37例接受安慰剂或Saroglitazar镁1或2mg治疗16周,选定1mg(0.97mg Saroglitazar)进入3期。
  • 3期随机148例至Saroglitazar组(n=97)或安慰剂组(n=51),治疗52周。

主要发现

  • 52周生化应答率Saroglitazar组56.7% vs 安慰剂组9.8%(差48.0%,95%CI 35.3-60.8,p<0.001)。
  • 基线ALP≤3xULN者生化应答率79.0% vs 14.3%,符合方案分析为83.1% vs 14.7%。
  • ALP正常化率8.2% vs 0%(差8.5%,95%CI 2.9-14,p=0.016)。
  • 基线5-D瘙痒评分≥12者第24周治疗差异-3.2分(95%CI -5.66至-0.82),但第52周未维持。
  • 不良事件发生率81.1% vs 90.5%,严重不良事件6.3% vs 11.1%。

关键数值与推荐

  • 主要终点为第52周生化应答:ALP<1.67×ULN且较基线下降≥15%,总胆红素低于ULN。
  • 关键次要终点为ALP正常化。

临床怎么用

  • 对于UDCA应答不佳或不耐受的PBC患者,Saroglitazar 0.97mg每日一次可作为潜在治疗选择。
  • 基线ALP≤3×ULN的患者可能从Saroglitazar治疗中获益更明显。
  • 治疗期间需监测ALP和胆红素以评估生化应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Saroglitazar, a dual PPAR alpha/gamma agonist, improved serum alkaline phosphatase (ALP) levels in patients with primary biliary cholangitis (PBC) in a phase 2a clinical trial. METHODS: EPICS-III is a phase 2b/3 adaptive, double-blind, randomized controlled trial in patients with PBC who had an inadequate response to or were intolerant of ursodeoxycholic acid (UDCA). In phase 2b, 37 participants received placebo or saroglitazar magnesium 1 or 2 mg for 16 weeks. Saroglitazar magnesium 1 mg (0.97 mg of saroglitazar) was selected for phase 3, which randomized 148 patients to saroglitazar (n=97) or placebo (n=51) for 52 weeks. The primary endpoint was biochemical response at week 52, defined as ALP <1.67 x ULN with ≥15% reduction from baseline and total bilirubin below ULN; the key secondary endpoint was ALP normalization. RESULTS: Baseline characteristics in the phase 3 efficacy population were comparable except for higher baseline ALP and other liver biochemistries in the saroglitazar group. Biochemical response was achieved in 56.7% versus 9.8% with placebo (difference, 48.0%; 95% CI, 35.3 to 60.8; p<0.001). Among participants with baseline ALP ≤3xULN, biochemical response rates were 79.0% versus 14.3%, and 83.1% versus 14.7% in the per-protocol analysis. ALP normalization occurred in 8.2% with saroglitazar versus 0% with placebo (difference, 8.5%; 95% CI, 2.9 to 14; p=0.016). Among participants with baseline 5-D Itch score ≥12, the week-24 treatment difference was -3.2 points (95% CI, -5.66 to -0.82) but was not maintained at week 52. Adverse events occurred in 81.1% with saroglitazar versus 90.5% with placebo, and serious adverse events occurred in 6.3% and 11.1%, respectively. CONCLUSION: Saroglitazar 0.97 mg significantly improved biochemical response and ALP normalization and was well tolerated over 52 weeks.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vuppalanchi R, Villamil A, Yilmaz Y, et al. A phase 2b/3 trial of saroglitazar in primary biliary cholangitis. Hepatology. 2026. PMID: 42929426. doi:10.1097/HEP.0000000000001895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。